5-HT2C Receptor Agonists for Weight Management and Satiety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current obesity treatments are inadequate due to lack of efficacy or unacceptable side effects, and there is a need for safe and effective therapies that address weight management and related disorders, particularly targeting the 5-HT2C receptor for weight reduction and psychiatric disorders.
Innovation Solution
Development of compounds that selectively modulate the 5-HT2C receptor to reduce food intake, induce satiety, and manage weight, while also addressing nicotine dependence and withdrawal, using a compound of Formula A in combination with a pharmaceutically acceptable carrier for administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current obesity treatments are used, then weight management is attempted, but efficacy is insufficient or side effects are unacceptable
Solution Approach 1:
The patent applies parameter changes by developing compounds with modified chemical structures (Formula A with specific R groups and ring systems) that alter the pharmacological parameters of 5-HT2C receptor interaction. This results in compounds with improved efficacy profiles and reduced side effects compared to existing treatments, as the structural modifications enable selective receptor binding with favorable safety characteristics.
2Productivity
If 5-HT2C receptor agonists are developed, then weight reduction and psychiatric disorder treatment are achieved, but compound selectivity and safety must be optimized
Solution Approach 1:
The patent applies local quality by designing compounds with specific local structural features (substituted phenyl rings, heterocyclic systems, and positioned functional groups in Formula A) that target the 5-HT2C receptor with high selectivity. These localized structural characteristics enable the compound to interact preferentially with the desired receptor subtype, achieving weight reduction efficacy while maintaining a favorable safety profile through selective binding.
3Adaptability or versatility
If multiple disorders are targeted, then treatment versatility is improved, but compound complexity increases
Solution Approach 1:
The patent applies universality by developing a single compound class (Formula A) that can treat multiple disorders including obesity, nicotine dependence, and psychiatric conditions. The compounds achieve this multi-functionality through their ability to modulate the 5-HT2C receptor, which is involved in diverse physiological processes. This single agent approach provides versatility across multiple indications without requiring complex combination therapies.
Data Source
AI summary
The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a 5-HT2C receptor-mediated disorder, such as, weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction and the like, obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders, urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a compound herein, optionally in combination with a supplemental agent.